Efficacy and safety of amrubicin‐based regimen used as first‐line for extensive‐disease small‐cell lung cancer: A meta‐analysis of randomized controlled trials

Abstract

Amrubicin-based regimen used as first-line had no survival benefits in patients with ED-SCLC. But it significantly improved ORR. Further well-conducted, large-scale trials are needed to validate these findings.